Press release
EliHealth Initiative Launches to Expand Access to Women's Health Solutions in Underserved Communities
Dedicated to Bridging Gaps in Women's Healthcare AccessibilityThe EliHealth Initiative [https://elihealth.org/], a nonprofit organization dedicated to improving women's health, has launched to eliminate financial and access barriers for underserved women. Many women-particularly in disadvantaged communities-delay seeking treatment for pelvic health conditions until symptoms worsen, leading to reduced quality of life, higher healthcare costs, and more complex care needs. EliHealth aims to reach these women earlier providing affordable, life-changing solutions to restore health, dignity, and confidence.
The EliHealth Initiative will focus on urinary incontinence, one of the most prevalent yet under-addressed women's health issues, impacting 1 in 3 women. While advanced, FDA-cleared treatments like Elitone are covered under Medicare and some insurance plans, high deductibles, copays, and out-of-pocket costs often prevent women from accessing care. Women resort to decreased activity, intimacy avoidance, poor sleep, increased urinary tract infections, and costly management with pads.
EliHealth tackles this challenge by providing assistance to access insurance coverage for women in need and distributing Elitone devices. Rather than simply managing symptoms, Elitone treats the root cause of incontinence with an easy, non-invasive, at-home solution that fits into women's lives.
"Our mission is simple: to ensure that financial barriers don't stand in the way of better health," said Gloria Kolb [https://www.linkedin.com/in/gloriakolb], a director of EliHealth. "We address incontinence because of its prevalence and its ability to deeply impact daily life, but the goal is deeper: to restore dignity and confidence, empowering women to reclaim active, fulfilling lives."
By providing treatment, the organization is committed to making a meaningful impact. It aims to support women like Sara L. who wrote, "I am a 34-year-old mother of four. I have severe pelvic floor dysfunction and other chronic health conditions that I struggle with. Unfortunately, there is not enough money to even make payments on the device. I ask if there is any program for an Elitone that might allow me the chance to overcome these issues that significantly impact my quality of life."
Women's health shouldn't be a privilege, it's a basic necessity. Yet, for too many women, necessary healthcare products remain out of reach. Elihealth Initiative is changing that.
To donate and make a difference for women, please visit https://elihealth.org/.
About Elihealth
EliHealth [https://elihealth.org/] is a nonprofit 501(c)(3) tax-exempt organization dedicated to improving women's health by addressing disparities in access to necessary medical products. Focused on underserved communities, EliHealth provides essential women's health solutions to individuals who face financial barriers to care. With an emphasis on accessibility, community partnerships, and education, the organization aims to empower women and promote equity in healthcare. EliHealth is committed to creating lasting change by ensuring that life-changing health solutions reach those who need them most.
Media Contact
Company Name: OtterPR
Contact Person: Pilar Lewis
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=elihealth-initiative-launches-to-expand-access-to-womens-health-solutions-in-underserved-communities]
Address:320 1st Ave N
City: St. Petersburg
State: Florida
Country: United States
Website: http://OtterPR.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release EliHealth Initiative Launches to Expand Access to Women's Health Solutions in Underserved Communities here
News-ID: 3791562 • Views: …
More Releases from ABNewswire
Rett Syndrome Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Compani …
DelveInsight's, "Rett Syndrome Pipeline Insight 2026" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Rett Syndrome pipeline landscape. It covers the Rett Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rett Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in…
Chronic Rhinosinusitis with Nasal Polyps Clinical Trial Pipeline Expands as 8+ C …
DelveInsight's "Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight 2026" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Chronic Rhinosinusitis with Nasal Polyps pipeline landscape. It covers the Chronic Rhinosinusitis with Nasal Polyps Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Rhinosinusitis with Nasal Polyps Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further…
Stargardt Disease Treatment Pipeline Shows Strong Momentum as 20+ Pharma Compani …
DelveInsight's "Stargardt Disease Pipeline Insight 2026" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Stargardt Disease pipeline landscape. It covers the Stargardt Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Stargardt…
Heart Failure Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Compani …
DelveInsight's, "Heart Failure Pipeline Insight 2026" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Heart Failure pipeline landscape. It covers the Heart Failure pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Heart Failure pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
